{"schema_version":"secwatch.filing_event.v1","accession":"0001411685-25-000004","form_type":"8-K","ticker":"VTGN","cik":"0001411685","company_name":"Vistagen Therapeutics, Inc.","filed_at":"2025-01-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.558189+00:00","generated_at":"2026-05-28T03:02:20.308616+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Vistagen enrolls first subject in fasedienol repeat dose study for social anxiety disorder","bullets":["Phase 2 exploratory trial evaluating repeat dose of fasedienol (3.2 mcg) in adults with SAD during a public speaking challenge.","Three arms: fasedienol+fasedienol (total 6.4 mcg), fasedienol+placebo (3.2 mcg), placebo+placebo; second dose 10 min after initial.","Study design mirrors ongoing PALISADE Phase 3 program including open-label extension.","CEO notes no FDA-approved acute treatment option exists for SAD despite high prevalence."],"urls":{"canonical":"https://secwatch.observer/filing/0001411685-25-000004","json":"https://secwatch.observer/filing/0001411685-25-000004.json","markdown":"https://secwatch.observer/filing/0001411685-25-000004.md","text":"https://secwatch.observer/filing/0001411685-25-000004.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1411685/000141168525000004/0001411685-25-000004-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1411685/000141168525000004/vtgn-20250110.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T03:02:20.308616+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}